| Bioactivity | PI3Kα-IN-22 (Compound 17) is an orally active, potent and selective inhibitor of PI3KαH1047R, with an IC50 of 1 nM for pAKT T47D AlphaLISA. PI3Kα-IN-22 can induce tumor regressions in the HCC1954 tumor model in mice[1]. |
| CAS | 2925030-26-6 |
| Formula | C24H23F2N5O3 |
| Molar Mass | 467.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ketcham JM, et al. Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein. J Med Chem. 2024 Mar 28;67(6):4936-4949. |
PI3Kα-IN-22
CAS: 2925030-26-6 F: C24H23F2N5O3 W: 467.47
PI3Kα-IN-22 (Compound 17) is an orally active, potent and selective inhibitor of PI3KαH1047R, with an IC50 of 1 nM for
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.